The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Insights from SEQTOR trial on treatment sequencing for advanced panNETs
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, explores findings from the SEQTOR trial (NCT02246127), which evaluated optimal sequencing in advanced pancreatic neuroendocrine tumors (panNET). The emerging role of radionuclides, alongside chemotherapy, everolimus, and sunitinib, introduces additional options to improve outcomes. The trial overall aims to refine treatment decisions and balance therapeutic strategies for long-term management of panNET. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
